TC
SAGE

TFS Capital’s Sage Therapeutics SAGE Stock Holding History

TFS Capital’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-15,755
Closed -$505K – 1151
2016
Q1 		$505K Sell
15,755
-13,143
-45% -$463K 0.07% 439
2015
Q4 		$1.69M Buy
+28,898
New +$1.43M 0.18% 200
2015
Q2 		– Sell
-25,069
Closed -$1.26M – 1065
2015
Q1 		$1.26M Buy
+25,069
New +$1.08M 0.12% 262

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

TFS Capital's SAGE Position: Q2 2016 in Review

TFS Capital sold out of Sage Therapeutics (SAGE) in Q2 2016, closing a stake of 15,755 shares — an estimated $505K sold.

TFS Capital first reported a position in SAGE in Q1 2015 and held it in 3 quarters. The position peaked at $1.69M in Q4 2015. 145 funds tracked by Wall St. Rank hold SAGE as of Q2 2016.

  • TFS Capital reported no remaining Sage Therapeutics position as of Q2 2016 after selling out during the quarter.
  • TFS Capital sold 15,755 Sage Therapeutics shares in Q2 2016, an estimated $505K.
  • TFS Capital first reported a position in Sage Therapeutics in Q1 2015 and held it in 3 quarters.
  • TFS Capital's Sage Therapeutics position peaked at $1.69M in Q4 2015.
  • 145 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2016.

Based on TFS Capital's 13F filing for Q2 2016, filed 11 Aug 2016.